Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has released a positive profit forecast for the fiscal year 2025, expecting revenue of at least 3 billion yuan, a growth of no less than 16% compared to 2024, and an adjusted net profit of at least 380 million yuan, representing a year-on-year increase of no less than 40% [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, which is an increase of at least 16% from the previous year [1]. - Adjusted net profit is expected to be no less than 380 million yuan, reflecting a year-on-year growth of at least 40% [1]. - The net profit is projected to be no less than 340 million yuan, indicating a year-on-year increase of at least 34% [1]. Group 2: Factors Influencing Performance - The company attributes its performance to two main factors: external acquisitions and organic business growth [3][4]. - The acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has expanded the company's business coverage and improved its adjusted net profit margin from 6.5% to 10.4% in the first half of 2025 [3]. - The company has also completed the acquisition of the third-largest beauty service brand, Siyuanli, further consolidating its position in the industry [3]. Group 3: Business Strategy and Future Outlook - The company is focusing on high-end female consumer groups in major cities, responding to the growing "self-indulgent consumption" demand, which has boosted same-store revenue [4]. - In November 2025, the company announced three strategic directions: "Super Brand," "Super Chain," and "Super Digitalization," aimed at exploring the high-end beauty service sector [5]. - The company plans to continue its dual-driven strategy of "organic growth + external acquisitions" and deepen its "dual beauty + dual healthcare" business model [5].

Core Viewpoint - Meili Tianyuan Medical Health Industry Co., Ltd. forecasts a positive profit outlook for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and adjusted net profit of at least 380 million yuan, representing a growth of no less than 40% [1] Group 1: Performance Growth Drivers - The company demonstrates strong resilience and growth potential through robust performance, attributed to two main factors: accelerated external expansion and strong internal growth momentum [2][3] - The successful acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has significantly enhanced the company's market share and business footprint in key areas, with Nairui'er’s adjusted net profit margin increasing from 6.5% to 10.4% post-acquisition [2] - The upcoming acquisition of the third-largest beauty service brand, Siyuanli, will further consolidate the top three brands under Meili Tianyuan, expanding its store network to over 734 locations [2] Group 2: Strategic Initiatives - The company is focusing on the "self-consumption" upgrade trend among women in high-tier cities, effectively driving same-store revenue growth [3] - Meili Tianyuan plans to implement three major strategic initiatives: Super Brand, Super Chain, and Super Digitalization, aiming to redefine high-end beauty services and reshape industry value [3] - The company will continue to pursue a dual-driven growth strategy of "internal growth + external acquisitions," enhancing its "dual beauty + dual health" business model to create sustainable value for customers, shareholders, employees, and partners [3]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has announced a positive profit forecast for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and a net profit of at least 3.4 billion yuan, reflecting strong resilience and growth potential amid economic fluctuations [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, representing a growth of at least 16% compared to 2024 [1]. - Adjusted net profit is expected to be no less than 3.8 billion yuan, indicating a year-on-year growth of at least 40% [1]. - Net profit is projected to be no less than 3.4 billion yuan, with a year-on-year increase of at least 34% [1]. Group 2: Strategic Expansion - The company is accelerating its external expansion through a dual growth strategy of "internal growth + external acquisitions," having successfully acquired the second-largest brand in China's beauty industry, Nairui'er, in 2024 [1]. - The integration of Nairui'er into Meili Tianyuan's brand matrix has significantly enhanced market share and business penetration in key areas of the Greater Bay Area [1]. - The acquisition has led to a strategic upgrade of the business model to a "dual beauty + dual healthcare" ecosystem, with Nairui'er’s adjusted net profit margin increasing from 6.5% before acquisition to 10.4% post-acquisition [1]. Group 3: Internal Growth and Market Position - Meili Tianyuan is capitalizing on the trend of "self-consumption" among women in high-tier cities, driving same-store revenue growth despite market challenges [3]. - The company is enhancing its medical business capabilities, with high-margin medical business revenue steadily increasing in 2025 [3]. - The store network has expanded to over 734 locations, capturing a significant market share in 20 first-tier and new first-tier cities [3]. Group 4: Future Strategies - The company will continue to implement its dual growth strategy of "internal growth + external acquisitions" and deepen the "dual beauty + dual healthcare" business model [5]. - A capital market value enhancement plan is set to be executed, aiming to create sustainable win-win outcomes for customers, shareholders, employees, and partners [5].

Core Viewpoint - Meili Tianyuan Healthcare (02373) expects to achieve a revenue of no less than RMB 3 billion in 2025, representing a growth of at least 16% compared to the same period in 2024, and an adjusted net profit of no less than RMB 380 million, reflecting a growth of at least 40% year-on-year [1] Group 1: Financial Projections - The company anticipates a net profit of no less than RMB 340 million in 2025, which is an increase of at least 34% compared to 2024 [1] - Revenue target for 2025 is set at no less than RMB 3 billion, indicating a growth of at least 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 380 million, marking a growth of at least 40% year-on-year [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong organic growth is noted, driven by an increase in brand momentum and customer numbers, leading to higher internal revenue growth and an increased proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "organic growth + external acquisitions" and aims to deepen its "dual beauty + dual healthcare" business model [1]

Core Viewpoint - The company anticipates achieving a revenue of no less than RMB 3 billion by 2025, representing a growth of at least 16% compared to the same period in 2024, alongside adjusted net profits of no less than RMB 3.8 billion, reflecting a growth of at least 40% [1] Group 1: Financial Projections - Expected revenue for 2025 is at least RMB 3 billion, a growth of no less than 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 3.8 billion, indicating a growth of at least 40% compared to 2024 [1] - Net profit is anticipated to be no less than RMB 3.4 billion, with a growth of at least 34% from 2024 [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong internal growth is noted, with an increase in brand momentum and customer numbers driving organic revenue growth, alongside a higher proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "internal growth + external acquisition" and aims to deepen its "dual beauty + dual healthcare" business model [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced the acquisition of 100% equity of Shanghai Siyuanli Industrial for a total consideration of 1.25 billion RMB, marking a key step in its "internal growth + external acquisition" strategy [1] Transaction Structure - The acquisition is structured as a "cash + acquisition loan + share issuance" plan, with cash consideration of approximately 840 million RMB, consisting of 330 million RMB from internal cash and 510 million RMB from bank financing; share consideration is about 410 million RMB, with the issuance of approximately 15.798 million shares at a price of 28.71 HKD per share [2] - After the transaction, Siyuanli will become a wholly-owned subsidiary of Meili Tianyuan, and its performance will be consolidated into the group's financial statements; existing shareholders' stakes will be diluted, with the controlling shareholder's stake expected to decrease by 3.07% to 45.70% post-transaction [2] Market Position and Brand Integration - The acquisition significantly strengthens Meili Tianyuan's market share, increasing the number of stores from 552 to 734, consolidating three leading brands in the Chinese beauty service market: Meili Tianyuan, Nairui, and Siyuanli [3] - The beauty service market in China is substantial, with the top 20 core cities accounting for about 40% of the market size; the acquisition will increase the number of stores in these cities from 360 to 491 [3] Competitive Advantage in High-End Market - The merger will enhance Meili Tianyuan's competitive edge in the high-end beauty market, with over 42% coverage of high-end commercial properties in the top 20 cities; the integration of 60,000 high-quality members from Siyuanli will increase the overall membership by 44% [4] - The integration of medical beauty resources will elevate service capabilities, with both companies having over 90% of their revenue from the top 20 cities [4] Valuation and Financial Attractiveness - Siyuanli's valuation is attractive, with a LTM P/E ratio of 14.8, lower than Meili Tianyuan's 29.5 and the industry average of 23.3, providing a safety margin for investors [5] - The acquisition is expected to replicate the successful integration path of Nairui, with potential for significant revenue enhancement and operational efficiency [5] Expected Outcomes - The acquisition is projected to be completed by December this year, with consolidation into financial statements expected in January 2026; the synergy effects are anticipated to drive EPS growth and enhance shareholder returns [6]

Core Viewpoint - The acquisition of 100% equity in Shanghai Siyuanli by Meili Tianyuan for a total consideration of 1.25 billion RMB is a key step in its "organic growth + external acquisition" strategy [1] Transaction Structure - The acquisition is structured as a diversified plan involving "cash + acquisition loan + share issuance," with cash consideration of approximately 840 million RMB, consisting of 330 million RMB from internal cash and 510 million RMB from bank financing [2] - The share consideration is about 410 million RMB, with the company issuing approximately 15.798 million shares at a price of 28.71 HKD per share to the seller [2] - Post-transaction, Siyuanli will become a wholly-owned subsidiary of Meili Tianyuan, and its performance will be consolidated into the group's financial statements [2] Market Position and Growth - The acquisition significantly strengthens Meili Tianyuan's market share, increasing the number of stores from 552 to 734, thereby solidifying its leading position in China's high-end beauty service market [3] - The top three brands in the Chinese beauty service market are Meili Tianyuan, Nairui, and Siyuanli, and the combined store network will enhance competitive advantages [3] Brand Integration and Competitive Advantage - The acquisition will facilitate the integration of three major brands, enhancing Meili Tianyuan's competitive edge in the high-end beauty market [4] - The combined coverage of high-end commercial properties in the top 20 core cities will exceed 42%, allowing access to nearly half of the high-end business districts [4] - The integration of 60,000 high-quality members from Siyuanli will increase the overall membership base by 44%, providing a foundation for cross-selling [4] Financial Attractiveness - Siyuanli's valuation is attractive, with a LTM P/E ratio of 14.8, lower than Meili Tianyuan's 29.5 and the industry average of 23.3, providing a safety margin for investors [5] - Siyuanli has a solid financial position with 360 million RMB in cash, sufficient to cover the initial payment, and an average annual operating cash flow of 240 million RMB to support loan repayments [5] Synergy and Future Growth - The company expects to replicate the successful integration path of Nairui, with potential for significant operational improvements and profit growth [5] - The anticipated synergies from the acquisition are expected to drive EPS growth even after considering dilution, benefiting both performance and shareholder returns [6]